Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic

NCT02109939 is registered in ClinicalTrials.gov with Assurex Health Inc. as lead sponsor.

NCT NCT02109939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02109939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
Lead sponsor
Assurex Health Inc.
Phase
Not applicable
Overall status
Completed
Start date
April 30, 2014
Completion date
July 31, 2017
Enrollment
1,398 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)